PXL proteome systems limited

http://www.sanford.com.au/sanford/Members/MarketInfo/News.asp?Sou...

  1. 4,756 Posts.
    http://www.sanford.com.au/sanford/Members/MarketInfo/News.asp?Source=RWE&ArticleID=247725

    Proteome Systems reaches biomarkers milestone
    09:10, Friday, 1 April 2005

    Sydney - Friday - April 1: (RWE Australian Business News) -
    Proteome Systems (ASX:PXL ) reports the achievement of a milestone under
    a collaborative agreement with the US-based HighQ Foundation for the
    discovery of biomarkers for monitoring the progression of Huntington's
    disease (HD) and the effectiveness of treatments in clinical trials.

    The milestone, involving proteomic analysis of diseased and
    normal individuals, was reached four months into the 18-month agreement
    and involved identification of the first candidate biomarkers for HD in
    clinical samples of plasma and cerebrospinal fluid.

    The milestone payment was US$300,000.

    HD is an inherited disease that affects about 1 in 10,000 adults
    in the Western world — usually between the ages of 30 and 50 years — and
    is invariably fatal.

    Huntington's disease is associated with neurodegeneration
    leading to a progressive decline in physical movement and mental
    processes.

    There is currently no effective treatment.

    ENDS

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.